By Journal Staff
Published: May 8, 2026
Introduction: A Life Divided
On World Ovarian Cancer Day, the global medical community and patient advocacy groups pause to reflect on the progress made in gynecological oncology while acknowledging the sobering realities that remain. Among the millions of stories that define this day, that of Susan Peluso stands as a poignant testament to the "before and after" of a cancer diagnosis. In March 2023, Peluso, then a healthy and active 54-year-old, joined the ranks of thousands of women diagnosed annually with high-grade serous ovarian cancer (HGSOC)—a disease often referred to as the "silent killer" due to its vague symptoms and late-stage presentation.
Peluso’s journey, marked by aggressive surgery, intensive chemotherapy, a fleeting period of remission, and a recent recurrence in early 2026, mirrors the clinical challenges faced by oncologists today. Her narrative is not merely a personal account of survival but a critical case study in the importance of medical self-advocacy, the psychological toll of chronic illness, and the vital role of specialized support organizations like Sharsheret.
Chronology: From Diagnosis to Recurrence (2023–2026)
The trajectory of Susan Peluso’s illness illustrates the rapid and often deceptive nature of ovarian malignancies. Her timeline serves as a roadmap for understanding the typical clinical path for late-stage patients.
The Initial Shock (March – May 2023)
In early 2023, Peluso began experiencing sharp rectal pain. Like many women, her symptoms were initially dismissed or misattributed; doctors first diagnosed the discomfort as simple muscle spasms. However, by March, the true cause was revealed: high-grade serous ovarian cancer, Stage 4B. By the time of diagnosis, the cancer had already metastasized to multiple organs beyond the pelvic cavity.
In May 2023, Peluso underwent a complete hysterectomy and a primary debulking surgery. In the world of oncology, "debulking" is a high-stakes procedure where surgeons attempt to remove as much visible tumor mass as possible to increase the efficacy of subsequent treatments.
The First Battle (June 2023 – February 2025)
Following surgery, Peluso underwent a rigorous protocol consisting of six rounds of platinum-based chemotherapy. This was followed by a maintenance phase involving 21 cycles of Avastin (Bevacizumab), a targeted therapy designed to prevent the growth of blood vessels that feed tumors. This treatment lasted through February 2025, during which Peluso maintained a disciplined "show up" mentality, integrating clinical visits into the fabric of her daily life.
The Fragile Peace of NED (2025)
For a period of 26 months following her initial chemotherapy, Peluso lived in the state of "No Evidence of Disease" (NED). For stage 4 patients, NED is a hard-won sanctuary, yet it is often shadowed by the statistical probability of recurrence. Peluso utilized this time to reclaim her life, finding hope in the absence of active symptoms while remaining vigilant.
The Second Front (January 2026 – Present)
The fragility of that peace was shattered in January 2026. Routine surveillance, including a CT scan and a liver MRI, confirmed a recurrence on January 31. By March 2, 2026, Peluso returned to the operating room for a second debulking surgery to address the new growths. On April 8, 2026, she began her second frontline battle with chemotherapy, a testament to the cyclical and relentless nature of the disease.
Supporting Data: Understanding High-Grade Serous Ovarian Cancer
To understand the gravity of Peluso’s situation, one must look at the clinical data surrounding High-Grade Serous Ovarian Cancer (HGSOC). HGSOC is the most common and most lethal subtype of ovarian cancer, accounting for approximately 70-80% of ovarian cancer deaths.
The Challenge of Late Detection
According to the American Cancer Society and the Ovarian Cancer Research Alliance (OCRA), only about 20% of ovarian cancers are found at an early stage. When found at Stage 1 or 2, the five-year survival rate can exceed 90%. However, Peluso’s diagnosis at Stage 4B places her in a category where the five-year survival rate historically hovers around 20-30%, though modern maintenance therapies are beginning to shift these numbers.
The lack of a reliable screening test—analogous to a mammogram for breast cancer or a colonoscopy for colorectal cancer—remains the greatest hurdle in gynecological oncology. Peluso’s experience with rectal pain being misdiagnosed as spasms highlights a common clinical pitfall: the symptoms of ovarian cancer (bloating, pelvic pain, urinary urgency, or GI distress) are frequently mistaken for benign conditions.
The Role of Maintenance Therapy
Peluso’s use of Avastin (Bevacizumab) for 21 cycles represents a standard of care for advanced-stage patients. Avastin is an angiogenesis inhibitor; by blocking the VEGF protein, it starves tumors of the nutrients they need to grow. While it does not "cure" the cancer, it is instrumental in extending the Period of Progression-Free Survival (PFS), as evidenced by Peluso’s two-year window of health.
Official Responses: The Infrastructure of Support
The medical treatment of cancer is only one facet of the patient experience. The psychological and social "debulking" of the trauma associated with a Stage 4 diagnosis requires institutional support. In her account, Peluso highlights Sharsheret, a national non-profit organization.
Sharsheret and Specialized Care
Sharsheret (Hebrew for "chain") was founded to support Jewish women and families facing breast and ovarian cancer, particularly those with genetic predispositions such as the BRCA mutation. However, the organization has expanded its reach to serve women of all backgrounds. Their approach emphasizes:
- Peer Support: Connecting patients with survivors who have navigated similar diagnoses.
- Genetic Counseling: Helping families understand the hereditary risks of HGSOC.
- Psychosocial Resources: Addressing the unique "scanxiety" (anxiety related to medical imaging) and the trauma of recurrence.
Advocacy groups like Sharsheret and the World Ovarian Cancer Coalition play a critical role in "official" responses by lobbying for increased research funding and public awareness campaigns. Their message on May 8, World Ovarian Cancer Day, focuses on the "Power of Solidarity," ensuring that patients like Peluso do not feel isolated when their "NED" status changes back to active treatment.
Implications: The Future of Advocacy and Patient Agency
Susan Peluso’s ongoing fight carries significant implications for the future of patient-physician relationships and the broader landscape of oncology.
The Necessity of Self-Advocacy
Peluso’s story is a clarion call for "listening to your body." In a medical system that is often overstretched, patients are increasingly required to be their own primary advocates. Peluso’s insistence on seeking answers despite an initial diagnosis of "spasms" likely contributed to her being able to undergo a successful first debulking. The implication for the public is clear: persistent, unexplained changes in abdominal or pelvic health must be investigated with transvaginal ultrasounds and CA-125 blood tests, even if those tools are not perfect screening methods.
The Psychological Toll of the "Recurrence Cycle"
The transition from a year of hope back into the "chemo chair" represents a profound psychological challenge. The medical community is beginning to recognize "Chronic Cancer Management" as a distinct phase of survivorship. Patients like Peluso are not just "fighting" a one-time infection; they are managing a chronic, life-threatening condition that requires long-term mental health support and a resilient spirit.
A Call to Action on World Ovarian Cancer Day
As of May 8, 2026, Susan Peluso remains "still here, still fighting, still hopeful." Her journey underscores the urgent need for:
- Early Detection Research: Investment in proteomic and genomic biomarkers that can identify HGSOC before it reaches Stage 3 or 4.
- Access to Clinical Trials: For patients facing recurrence, access to Phase II and III trials for PARP inhibitors and immunotherapies is vital.
- Global Awareness: Reducing the stigma and silence surrounding gynecological health to ensure that symptoms are reported and taken seriously by primary care physicians.
Conclusion: Beyond the Diagnosis
Susan Peluso’s narrative is a powerful reminder that a Stage 4 diagnosis is a chapter, not the entire book. While the clinical facts of her case are sobering, her resolve—supported by medical science and organizations like Sharsheret—highlights the shift in modern oncology toward treating the whole person rather than just the pathology. On this World Ovarian Cancer Day, Peluso’s voice joins a global chorus demanding better outcomes, faster research, and a future where "before and after" is no longer a divide defined by a lack of early detection.
As she continues her chemotherapy in the spring of 2026, her message to the world is one of vigilant optimism: "This is not the chapter I wanted—but it is the one I’m living." It is a chapter written with courage, serving as an inspiration for others to listen, to ask, and to never stop fighting for answers.
About the Author
